Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $5.83 in the prior trading day, Monte Rosa Therapeutics Inc (NASDAQ: GLUE) closed at $5.67, down -2.74%. In other words, the price has decreased by -$2.74 from its previous closing price. On the day, 0.68 million shares were traded. GLUE stock price reached its highest trading level at $5.87 during the session, while it also had its lowest trading level at $5.48.
Ratios:
Our goal is to gain a better understanding of GLUE by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.94 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.18. For the most recent quarter (mrq), Quick Ratio is recorded 2.40 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Downgraded its rating to Equal Weight and sets its target price to $11 from $14 previously.
On February 15, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $11.
Wells Fargo Upgraded its Equal Weight to Overweight on January 03, 2023, while the target price for the stock was maintained at $18.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 24 ’25 when Leo Chandra P. bought 10,000 shares for $5.84 per share. The transaction valued at 58,383 led to the insider holds 10,000 shares of the business.
Versant Venture Capital VI, L. sold 89,990 shares of GLUE for $869,240 on Oct 28 ’24. The 10% Owner now owns 2,007,948 shares after completing the transaction at $9.66 per share. On Oct 29 ’24, another insider, Versant Venture Capital VI, L., who serves as the 10% Owner of the company, sold 67,905 shares for $9.16 each. As a result, the insider received 621,801 and left with 1,573,453 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GLUE now has a Market Capitalization of 358601984 and an Enterprise Value of 19326686. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.61 while its Price-to-Book (P/B) ratio in mrq is 1.56. Its current Enterprise Value per Revenue stands at 0.256 whereas that against EBITDA is -0.265.
Stock Price History:
The Beta on a monthly basis for GLUE is 1.45, which has changed by -0.19460225 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, GLUE has reached a high of $12.40, while it has fallen to a 52-week low of $3.21. The 50-Day Moving Average of the stock is -7.97%, while the 200-Day Moving Average is calculated to be -6.43%.
Shares Statistics:
The stock has traded on average 744.80K shares per day over the past 3-months and 967910 shares per day over the last 10 days, according to various share statistics. A total of 61.51M shares are outstanding, with a floating share count of 46.00M. Insiders hold about 25.21% of the company’s shares, while institutions hold 80.20% stake in the company. Shares short for GLUE as of 1740700800 were 8042209 with a Short Ratio of 10.80, compared to 1738281600 on 8074830. Therefore, it implies a Short% of Shares Outstanding of 8042209 and a Short% of Float of 23.91.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
